13 Pharmaceuticals Stocks to Sell Now

13 Pharmaceuticals Stocks to Sell Now

The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Eli Lilly and Company (LLY) declines this week from a C to a D. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.

This is a rough week for Bristol-Myers Squibb Company (BMY). The company’s rating falls to D from the previous week’s C. Bristol-Myers Squibb Company is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.

Prestige Brands Holdings, Inc. (PBH) earns a D this week, moving down from last week’s grade of C. Prestige Brands Holdings, Inc. distributes over-the-counter healthcare and household cleaning products to retail stores in the United States, Canada and other international markets. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PBH stock.

Astrazeneca PLC Sponsored ADR’s (AZN) rating weakens this week, dropping to a D versus last week’s C. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Flex Pharma, Inc. (FLKS) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLKS stock.

Slipping from a D to a F rating, Collegium Pharmaceutical, Inc. (COLL) takes a hit this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of COLL stock.

Akari Therapeutics Plc Sponsored ADR (AKTX) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AKTX stock.

Egalet Corporation (EGLT) slips from a D to a F this week. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EGLT stock.

This week, Novogen Limited Sponsored ADR (NVGN) drops from a C to a D rating. Novogen Limited Sponsored ADR is a medical services company which develops and markets pharmaceutical products in Australia. For more information, get Portfolio Grader’s complete analysis of NVGN stock.

DURECT Corporation (DRRX) experiences a ratings drop this week, going from last week’s D to a F. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

This week, EyeGate Pharmaceuticals, Inc.’s (EYEG) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EYEG stock.

Jaguar Animal Health, Inc. (JAGX) declines this week from a C to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of JAGX stock.

This is a rough week for VIVUS, Inc. (VVUS). The company’s rating falls to D from the previous week’s C. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The company also gets F’s in sales growth, earnings revisions, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/09/13-pharmaceuticals-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC